Pre-order Enquiry
Request Free Sample
Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
SKU ID : GIR-13841647 | Publishing Date : 13-Feb-2019 | No. of pages : 116
Request Sample
Request Customization
Check Discounts
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
Scope of the Report:
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44% in 2015.
The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28% in 2015.
Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK, Sanofi are the leader of the industry, and hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.
The worldwide market for Glucagon Like Peptide-1 (GLP-1) Agonists is expected to grow at a CAGR of roughly 14.3% over the next five years, will reach 11700 million US$ in 2024, from 5240 million US$ in 2019, according to a new study.
This report focuses on the Glucagon Like Peptide-1 (GLP-1) Agonists in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Novo Nordisk
AstraZeneca
Eli Lilly
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Market Segment by Applications, can be divided into
Hospital
Pharmacy
Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Glucagon Like Peptide-1 (GLP-1) Agonists product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, with price, sales, revenue and global market share of Glucagon Like Peptide-1 (GLP-1) Agonists in 2017 and 2018.
Chapter 3, the Glucagon Like Peptide-1 (GLP-1) Agonists competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Glucagon Like Peptide-1 (GLP-1) Agonists breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Glucagon Like Peptide-1 (GLP-1) Agonists market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Glucagon Like Peptide-1 (GLP-1) Agonists sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Scope of the Report:
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44% in 2015.
The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28% in 2015.
Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK, Sanofi are the leader of the industry, and hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.
The worldwide market for Glucagon Like Peptide-1 (GLP-1) Agonists is expected to grow at a CAGR of roughly 14.3% over the next five years, will reach 11700 million US$ in 2024, from 5240 million US$ in 2019, according to a new study.
This report focuses on the Glucagon Like Peptide-1 (GLP-1) Agonists in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Novo Nordisk
AstraZeneca
Eli Lilly
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Market Segment by Applications, can be divided into
Hospital
Pharmacy
Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Glucagon Like Peptide-1 (GLP-1) Agonists product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, with price, sales, revenue and global market share of Glucagon Like Peptide-1 (GLP-1) Agonists in 2017 and 2018.
Chapter 3, the Glucagon Like Peptide-1 (GLP-1) Agonists competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Glucagon Like Peptide-1 (GLP-1) Agonists breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Glucagon Like Peptide-1 (GLP-1) Agonists market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Glucagon Like Peptide-1 (GLP-1) Agonists sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
